An independent and potentially powerful anti-cancer effect of PP2A/PP5 inhibition stems from the finding that LB-100 also enhances the efficacy of immune checkpoint blockade in different cancer models by fostering T-cell and cGAS-STING activation (Apostolidis et al, 2016; Ho et al, 2018; Maggio et al, 2020). The gene discussed is PTPA; the disease is cancer.